In July, biopharma deal values surged to $20.68 billion, a 61% increase from June's $12.82 billion. The boost pushed the total deal value for the first seven months of 2024 to $119.99 billion, marking the highest amount raised through July in BioWorld‘s records.

Meaty Oric? Finding substance in rise of new PC approaches

Aug. 9, 2024

By Randy Osborne

Novartis AG CEO Vas Narasimhan during the company’s July 18 second-quarter earnings call said his firm was “still in the midst of completing” the buyout disclosed in February of Morphosys AG, of Munich, for €2.7 billion (then US$2.9 billion), which brought worldwide rights to pelabresib, the small-molecule BET inhibitor for myelofibrosis.

Neuren’s NNV-2591 positive in Angelman syndrome phase II trial

Aug. 9, 2024

By Tamra Sami

Neuren Pharmaceuticals Ltd.’s NNZ-2591 met the primary endpoints in a phase II trial in children with Angelman syndrome, with improvements seen in clinically important aspects of the disease, including communication, behavior, cognition and motor abilities, Neuren CEO Jon Pilcher said during an Aug. 9 conference call.

Businesspeople shaking hands, meeting with cityscape, charts

Med-tech deals July 2024

Med-tech deal and M&A values rise in July, fall short of recent years

Aug. 9, 2024

By Amanda Lanier

In July, med-tech deal values surged to $200.88 million, up 116% from June's $93.07 million and ranking as the second-highest monthly total for 2024, behind only February’s $255.61 million.

As markets tumble, biotech expected to weather economic downturn

Aug. 6, 2024

By Amanda Lanier

Stocks tumbled on Aug. 5, with the Dow Jones Industrial Average falling more than 1,000 points amid a disappointing jobs report released by the U.S. Labor Department on Aug. 2. The BioWorld Stock Index, which tracks approximately 510 U.S. biopharma stocks, was up 17.27% for the year on July 26 before closing Aug. 5 up only 3.47%, representing a significant drop.

China to deepen health care reforms, boost primary care capacity

Aug. 6, 2024

By Tamra Sami

China will deepen its health care reforms and will focus on enhancing its public health care capacity at the primary care level and at public hospitals, according to resolutions passed at the third plenary session of the 20th Central Committee of the Communist Party of China in July.

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Analysis and data insight RSS

Analysis and data insight
RSS